Download PDF
Hamostaseologie 2000; 20(04): 167-172
DOI: 10.1055/s-0037-1619488
Original article
Schattauer GmbH

Klinische Ergebnisse der Behandlung der koronaren Herzkrankheit mit Wachstumsfaktoren

Clinical results of the treatment of coronary artery disease with growth factors
Th. Hoppert
1   Klinik für Thorax-, Herz- und Gefäßchirurgie, Klinikum Fulda (Direktor: Professor Dr. Th. J. Stegmann)
,
R. Ibing
2   Medizinische Klinik I, Klinikum Fulda (Direktor: Prof. Dr. T. Bonzel)
,
A. Schneider
1   Klinik für Thorax-, Herz- und Gefäßchirurgie, Klinikum Fulda (Direktor: Professor Dr. Th. J. Stegmann)
,
M. Popp
1   Klinik für Thorax-, Herz- und Gefäßchirurgie, Klinikum Fulda (Direktor: Professor Dr. Th. J. Stegmann)
,
Th. J. Stegmann
1   Klinik für Thorax-, Herz- und Gefäßchirurgie, Klinikum Fulda (Direktor: Professor Dr. Th. J. Stegmann)
› Author Affiliations
Further Information

Publication History

Publication Date:
22 December 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die aktuellen Behandlungsmethoden der koronaren Herzkrankheit zielen auf Minimierung des Infarktrisikos und Reduktion der Symptome durch Senkung des myokardialen Sauerstoffbedarfs, durch Verbesserung der myokardialen Perfusion sowohl medikamentös als auch mechanisch durch PTCA oder Bypasschirurgie und durch Prävention einer weiteren Progression der Erkrankung. Trotz des hohen technischen Standards der interventionellen oder operativen Verfahren der myokardialen Revaskularisation sind diese bei Patienten mit diffuser Arteriosklerose und peripherem Gefäßbefall nicht anwendbar. Die Induktion der Angiogenese durch humane angiogenetische Wachstumsfaktoren entwickelt sich speziell bei dieser Patientengruppe zu einer neuen Therapiemodalität und stellt neben medikamentöser Therapie, PTCA und Bypasschirurgie ein viertes, neuartiges Behandlungsprinzip der koronaren Herzkrankheit dar. »Polypeptide Fibroblast Growth Factor« (FGF) und »Vascular Endothelial Growth Factor« (VEGF) scheinen einen besonders starken Effekt im Hinblick auf die Induktion der Angiogenese im hypoxischen Gewebe auszuüben.

Summary

Currently available approaches for treating coronary heart disease aim to relieve symptoms and the risk of myocardial infarction by reducing myocardial oxygen demand, increasing myocardial perfusion pharmcologically or mechanically by angioplasty or bypass surgery and by preventing further progression of the disease. Despite the high technical standarts of bypass surgery and interventional procedures, patients with diffuse atherosclerosis are not amenable to these techniques. Therapeuthic induction of angiogenesis by human angiogenic growth factors is evolving to be a fourth, new principle of treatment of atherosclerotic cardiovascular disease, especially for this group of patients. The polypeptides fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) seem to be powerful stimulators of angiogenesis in hypoxic tissue.

Schlüsselwörter

Angiogenese - Wachstumsfaktoren - Fibroblast Growth Factor - koronare Herzkrankheit

Keywords

Angiogenesis - growth factors - fibroblast growth factor - coronary heart disease
 

  • Literatur

  • 1 Baird A, Bohlen P, Esch F. et al. Acidic fibroblast growth factor (FGF) from bovine brain: amino-terminal sequence and comparison with basic FGF. EMBO J 1985; 4: 1951-6.
    PubMedGoogle Scholar
  • 2 Battler A, Scheinowitz M, Bor A. et al. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J Am Coll Cardiol 1993; 22: 2001-6.
    CrossrefPubMedGoogle Scholar
  • 3 Baumgartner J, Pieczek A, Manor O. et al. Constitutive expression of ph VEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischaemia. Circulation 1998; 97: 1114-23.
    CrossrefPubMedGoogle Scholar
  • 4 Burgess WH, Mehrman T, Friesel R. et al. Multiple forms of endothelial cell growth factor. Rapid isolation and biological and chemical characterization. J Biol Chem 1985; 260: 11389-92.
    PubMedGoogle Scholar
  • 5 Carmeliet P. et al. Abnormal blood vessel development and lethality in embryos lackings a single VEGF allele. Nature 1996; 380: 435-9.
    CrossrefPubMedGoogle Scholar
  • 6 Cuevas P, Gonzalez AM, Carceller F, Baird A. Vascular response to basic fibroblast growth factor when infused onto the normal adventita or into the injured media of the rat carotid artery. Circulation Res 1991; 69: 360-9.
    CrossrefPubMedGoogle Scholar
  • 7 Fasol R, Schumacher B, Schlaudraff K. et al. Experimental use of a modified fibrin-glue to induce site-directed angiogenesis from the aorta to the heart. J Thorac Cardiovasc Surg 1994; 107: 1432-9.
    PubMedGoogle Scholar
  • 8 Ferrara N, Carrer-Moore K, Chen H. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-42.
    CrossrefPubMedGoogle Scholar
  • 9 Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
    CrossrefPubMedGoogle Scholar
  • 10 Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-7.
    CrossrefPubMedGoogle Scholar
  • 11 Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
    CrossrefPubMedGoogle Scholar
  • 12 Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-63.
    CrossrefPubMedGoogle Scholar
  • 13 Friesel R, Burgess WH, Mehrman T. et al. The characterization of the receptor for endothelial cell growth factor by covalent ligand attachment. J Biol Chem 1986; 261: 7581-4.
    PubMedGoogle Scholar
  • 14 Harada K, Grossman W, Friedman M. et al. Basic fibroblast growth factor improves myocardial function in chronically ischaemic porcine hearts. J Clin Invest 1994; 94: 623-30.
    CrossrefPubMedGoogle Scholar
  • 15 Inoùe M, Hiroshi I, Ueda M. et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions. Circulation 1998; 98: 2108-16.
    CrossrefPubMedGoogle Scholar
  • 16 Isner JM, Pieczek A, Schainfeld R. et al. Clinical evidence of angiogenesis after arterial gene transfer of ph VEGF165 in patient with ischaemic limb. Lancet 1996; 348: 370-4.
    CrossrefPubMedGoogle Scholar
  • 17 Kuzuya M, Satake S, Esaki T. et al. Induction of angiogenesis by smooth muscle cell-derived factor: possible role in neovascularization in atherosclerotic plaque. J Cell Physiol 1995; 164: 658-67.
    CrossrefPubMedGoogle Scholar
  • 18 Laham RJ, Sellke FW, Edelman ER. et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery. Circulation 1999; 100: 1865-71.
    CrossrefPubMedGoogle Scholar
  • 19 Losordo DW, Vale PR, Symes JF. et al. Gene therapy for myocardial angiogenesis. Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischaemia. Circulation 1998; 98: 2800-4.
    CrossrefPubMedGoogle Scholar
  • 20 Lazarous DF, Scheinowitz M, Shou M. et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 1996; 94: 1074-82.
    CrossrefPubMedGoogle Scholar
  • 21 Maciag T, Mehrman T, Friesel R. et al. Heparin binds endothelial cell growth factor, the principal mitogen in the bovine brain. Science 1984; 225: 932-5.
    CrossrefPubMedGoogle Scholar
  • 22 Nabel EG, Yang ZY, Plautz G. et al. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature 1993; 362: 844-6.
    CrossrefPubMedGoogle Scholar
  • 23 Nomura M, Yamagishi S, Havada S. et al. Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxiainduced proliferation of endothelial cells and pericytes. J Biol Chem 1995; 270: 28316-24.
    CrossrefPubMedGoogle Scholar
  • 24 Risau W, Flamme I. Vasculogenesis. Ann Rev Cell Dev Biol 1995; 11: 79-91.
    PubMedGoogle Scholar
  • 25 Rosengart TK, Lee LY, Patel SR. et al. Angiogenesis gene therapy. Circulation 1999; 100: 468-74.
    CrossrefPubMedGoogle Scholar
  • 26 Schaper W, Ito W. Molecular mechanisms of collateral vessel growth. Circ Res 1996; 79: 911-9.
    CrossrefPubMedGoogle Scholar
  • 27 Schlaudraff K, Schumacher B, von Specht BU. et al. Growth of “new” coronary vascular structures by angiogenetic growth factors. Eur J Cardiothorac Surg 1993; 7: 637-44.
    CrossrefPubMedGoogle Scholar
  • 28 Schumacher B, Pecher P, von Specht BU. et al. Induction of neoangiogenesis in ischaemic myocardium by human growth factors. First clinical results of a new treatment of coronary heart disease. Circulation 1998; 97: 645-50.
    CrossrefPubMedGoogle Scholar
  • 29 Schumacher B, Stegmann T, Pecher P. The stimulation of neoangiogenesis in the ischaemic human heart by the growth factor FGF: first clinical results. J Cardiovasc Surg 1998; 39: 783-9.
    PubMedGoogle Scholar
  • 30 Sellke FW, Wang SY, Stamler A. et al. Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischaemia. Surgery 1996; 120: 182-8.
    CrossrefPubMedGoogle Scholar
  • 31 Shing Y, Folkman J, Sullivan R. et al. Heparin affinity: purification of a tumour-derived capillary endothelial cell growth factor. Science 1984; 223: 1296-8.
    CrossrefPubMedGoogle Scholar
  • 32 Stegmann TJ. FGF-1: a human growth factor in the induction of neoangiogenesis. Exp Opin Invest Drugs 1998; 7: 2011-5.
    CrossrefPubMedGoogle Scholar
  • 33 Stegmann TJ. New approaches to coronary heart disease: Induction of neovascularization by growth factors. BioDrugs 1999; 11: 301-8.
    CrossrefPubMedGoogle Scholar
  • 34 Stegmann TJ, Hoppert T. Combined local angiogenesis and surgical revascularization for coronary artery disease. Current Intervent Cardiol Reports 1999; 1: 172-8.
    PubMedGoogle Scholar
  • 35 Stegmann TJ. Intramyocardial injection of acidic fibroblast growth factor: adjunct to bypass surgery and monotherapy for coronary heart disease. In: Kornowski R, Epstein SE, Leon MB. (Hrsg). Handbook of Myocardial Revascularization and Angiogenesis. London: M. Dunitz Ltd; 2000: 201-14.
    Google Scholar
  • 36 Stegmann TJ, Hoppert T, Schlürmann W, Gemeinhardt S. First angiogenic treatment of coronary heart disease by FGF-1: Long-term results after three years. J Cardiac Vascular Regeneration 2000; 1: 5-10.
    PubMedGoogle Scholar
  • 37 Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenetic agent. J Biol Chem 1996; 271: 603-6.
    CrossrefPubMedGoogle Scholar
  • 38 Thompson JA, Haudenschild CC, Anderson KD. et al. Heparin-binding growth factor induces the formation of organoid neovascular structures in vivo. Proc Natl Acad Sci USA 1989; 86: 7928-32.
    CrossrefPubMedGoogle Scholar
  • 39 Tudor RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDT/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 1995; 95: 1798-807.
    CrossrefPubMedGoogle Scholar
  • 40 Unger EF, Banai S, Shou M. et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol 1994; 266: 1588-95.
    PubMedGoogle Scholar
  • 41 Ware JA, Simons M. Angiogenesis in ischaemic heart disease. Nat Med 1997; 3: 158-64.
    CrossrefPubMedGoogle Scholar
  • 42 Yanagisawa-Miwa A, Uchida Y, Nakamura F. et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992; 257: 1401-2.
    CrossrefPubMedGoogle Scholar